Zacharowski K

Language: English
References: 7
Page: 227
PDF size: 78.69 Kb.

Text Extraction

In patients undergoing cardiac surgery, perioperative coagulopathy and the use of allogenic blood products are independently associated with increases in mortality and major perioperative cardiac and non-cardiac adverse events. Early and specific diagnosis and effective and targeted therapy of the underlying hemostatic pathology are of high clinical relevance. In this context, algorithm-based hemostatic therapy shows to be superior to empiric hemostatic therapy that is based on clinical judgment.

REFERENCES

1. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116:2544-2552.

2. Moulton MJ, Creswell LL, Mackey ME, et al. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996;111:1037-1046.

3. Goodnough LT: Risks of blood transfusion. Crit Care Med. 2003;31:678-686.

4. Ak K, Isbir CS, Tetik S, et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg. 2009;24:404-410-

5. Westbrook AJ, Olsen J, Bailey M, et al. Protocol based on thromboelastograph (TEG) outperforms physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study. Heart Lung Circ. 2009;18:277-288.

6. Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg. 2010;140:1117-1124.e2.

7. Weber CF, Görlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012;117:531-547.